130 likes | 1.75k Views
Revised National Tuberculosis Control Programme (RNTCP) in India: . China 15%. India 30%. Indonesia. 10%. Bangladesh. 4%. Pakistan. Other 28%. 4%. Philippines. 3%. Nigeria. 3%. South Africa. Russia. 2%. 1%. India accounts for nearly one third of the global TB burden.
E N D
Revised National Tuberculosis Control Programme (RNTCP) in India:
China 15% India 30% Indonesia 10% Bangladesh 4% Pakistan Other 28% 4% Philippines 3% Nigeria 3% South Africa Russia 2% 1% India accounts for nearly one third of the global TB burden
Organization Structure Central Level State TB Cell Nodal point for TB control District TB Centre Around 450 units One/ 0.5 m (.25 m in hilly/ difficult/ tribal area) Around 1700 already established Tuberculosis Unit One/ 0.1 m (0.05 m in hilly/ difficult/ tribal area) Around 8000 already established Microscopy Centre DOT Provider – MPW, NGO, PP, Comm Vol DOT Centre
Peripheral Health Institute Monthly Report Tuberculosis Unit Quarterly Report within 7 days of end of quarter District TB Centre Feedback Quarterly Report within 20 days State TB Cell Central TB Division Drug Management System Feedback More than 90% of reports received electronically at CTD
Patient Wise Box (PWB) • Choice of Drugs in India – PWB • Improved Blister Packs in patient-wise boxes introduced have proved to be very effective • Makes calculations, management & distribution much easier for the programme officers vis-à-vis the loose drugs • Makes sure full course of treatment is available for each patient who is initiated on treatment resulting in development of improved confidence of the patient in the public health system. • Regimen : 3 categories of treatment identified depending on the type of patient, period of treatment being 6-8 months thrice weekly • Presentation: The drugs are blister packed with IP and CP pouches in a PWB containing whole course of treatment for each patient.
Achievements of RNTCP • 830 million population covered by DOTS • Treatment success exceeded global target of 85% • Case detection in DOTS areas recently attained global target of 70% • Nearly 3 million patients put on treatment, 900,000 in 2003 alone • Cure rate more than doubled vs. non-DOTS areas • Deaths reduced 7-fold vs. non-DOTS areas • Over 500,000 lives saved • Recent baseline ARTI survey completed - repeat survey at 3-5 years intervals planned
Challenges • Expansion of DOTS to the entire country by 2005 • Maintain quality whilst rapid expansion • Strengthen partnerships with ESIS, Railways, TB hospitals, Medical colleges, Private sector • Capacity building of States for decentralization of programme and financial management and monitoring • Improve quality of implementation in urban areas • Intensification of IEC • Addressing issues on: • Human resource development • TB-HIV • Drug resistance • Ensuring long term funding for sustainability